Paul D. Kessler is CMO & SVP Clinical +1 at NABI BIOPHARMACEUTICALS (NABI). They have made 5 open-market trades across 1 company since 2008, most recently 2012-04-05.
CIK 0001428524
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NABI | 105,128 | — |
Shares reported on the most recent Form 4, priced at the 2012-04-09 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NABI | SELL | 2012-04-05 | 2012-04-09 | $1.90 | $10K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2011-05-16 | 2011-05-18 | $5.51 | $68K | N/A | N/A | N/A |
| NABI | SELL | 2011-04-05 | 2011-04-05 | $5.76 | $50K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2011-01-05 | 2011-01-07 | $5.65 | $17K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-05-17 | 2010-05-19 | $5.71 | $86K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-04-05 | 2010-04-07 | $5.34 | $28K | N/A | N/A | N/A |
| NABI | SELL | 2009-11-23 | 2009-11-25 | $5.00 | $3K | N/A | N/A | N/A |
| NABI | SELL | 2009-11-19 | 2009-11-23 | $4.90 | $89K | N/A | N/A | N/A |
| NABI | SELL | 2008-03-05 | 2008-03-07 | $3.74 | $9K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.